Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis

Liyen Katrina Kan, Kate Drummond, Martin K. Hunn, David Williams, Terence J. O'Brien, Mastura Monif

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood–brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. There is a need for biomarkers that would both overcome the complexity of the disease and allow for a minimally invasive means of detection and analysis. This is a comprehensive review evaluating the potential of current cellular, proteomic and molecular biomarker candidates for glioma. Significant hurdles faced in glioma diagnostics and therapy are also discussed here.
Original languageEnglish
Article numbere000069
Number of pages10
JournalBMJ Neurology Open
Volume2
Issue number2
DOIs
Publication statusPublished - Aug 2020

Cite this